AbbVie to Buy Cerevel Therapeutics for $8.7 Billion — Update
By Ben Glickman
AbbVie will acquire neuroscience-drug maker Cerevel Therapeutics Holdings for $45 a share, giving the company an equity value of about $8.7 billion.
The deal is AbbVie's second major acquisition announced in the last two weeks, after the pharmaceutical giant announced Nov. 30 it would acquire ImmunoGen for $10 billion.
Cerevel is currently developing potential candidates to treat schizophrenia, Parkinson's disease and mood disorders.
AbbVie said the deal complements its existing neuroscience portfolio currently on the market.
"AbbVie will leverage its deep commercial capabilities, international infrastructure and regulatory and clinical expertise to deliver substantial shareholder value with multibillion-dollar sales potential across Cerevel's portfolio of assets," said Chief Executive Richard Gonzalez.
AbbVie said the deal is expected to close in the middle of 2024 and will be accretive to adjusted earnings starting in 2030.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
December 06, 2023 16:55 ET (21:55 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Stocks to Buy While They’re Trading at Big Discounts
-
Markets Brief: Tech Stocks Lead Ahead of Nvidia Earnings
-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
Should You Buy and Hold an Artificial Intelligence Portfolio?
-
3 Cheap and Dependable Dividend-Growth Stocks to Buy
-
The Best Bank Stocks to Buy
-
After Earnings, Is Roblox Stock a Buy, Sell, or Fairly Valued?
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?